Navigation Links
ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
Date:1/18/2008

- Irish and UK Blood services continue pre-adoption clinical evaluation of

filter - Recent case of vCJD now means that all the population is susceptible to

the disease - Increased concerns over "second wave" of vCJD in individuals with much

longer incubation times

- P-Capt(R) prion reduction filter still the only proven method of

protecting against potential transmission of the disease in blood - ProMetic and MacoPharma gearing up for implementation in watershed year

for the product

CAMBRIDGE, UK and LILLE, France, Jan. 18 /PRNewswire-FirstCall/ - The successful completion of two human clinical studies performed on volunteers using the P-Capt(R) prion reduction filter for red cell concentrates has been announced by ProMetic Life Sciences Inc. ("ProMetic") and MacoPharma. The clinical studies evaluated the effect of the filter on units of red cell concentrate collected from human volunteers, to ensure that the use of the filter had no negative effect on the red blood cells themselves. Data demonstrated no negative impact.

"These studies represent the first use of the P-Capt(R) prion filter in humans and the results demonstrate that not only is the product effective in reducing the risk of transmission of variant Creutzfeldt-Jakob disease ("vCJD") by blood transfusion but also there is no impact of the treatment on the blood itself," stated Mr. Christophe Vinzia, MacoPharma's Director of Business Development. "This represents a major milestone and we anticipate the positive results will encourage early adoption of the product in the UK and Ireland".

This latest news comes after reports of a previously unseen 'vv' genotype individual contracting vCJD. "Reports of the vv genotype individual now mean that any individual is susceptible to contracting vCJD," commented Dr. Peter Edwardson, ProMetic's Vi
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013   NineSigma , Inc., of ... following its launch, NineSights.com is now the ... for the worldwide community of innovators. From ... sustainability experts, NineSights stands out for its large community ... and technical disciplines, all vetted by NineSigma. The community ...
(Date:6/19/2013)... Bloomington, Indiana (PRWEB) June 19, 2013 ... Valentine joined the speaking faculty at 2013’s BioLogistics ... , The conference, coordinated by Cold Chain IQ ... surrounding biologics. This “complexity” is, in part, attributed ... medicine. , “Implicit within these trends is ...
(Date:6/19/2013)... San Diego, CA (PRWEB) June 19, 2013 ... quality pipettes, Pipette.com is now stocked with Simport’s Dropette® ... , all aimed at the customer doing basic biology, ... blood work, and serology). , For over 35 years, ... and disposable plastic labware - products like the Simport ...
(Date:6/18/2013)... 18, 2013 (PRWEB) June 18, 2013 ... attendance system in North America, has introduced AccountLinx ... data and payroll records between ExakTime’s software and ... automates ExakTime software setup and keeps employee databases ... data from a business’ current payroll software, directly ...
Breaking Biology Technology:NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2ExakTime Introduces AccountLinx Plus 2
... Aug. 21 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... leading Chinese firm specializing in the ... probiotics products,today announced it signed a ... Ltd. ("Square Pharmaceutical") to supply probiotics ...
... 29% and adjusted EPS* of $0.35 ... increased 218% -, - Total Fiscal Year Revenues of $79.8M increased 15% ... $0.99 increased ... reported the results for its fourth quarter and fiscal,year ended June 30, 2008., Fourth ...
... YORK, MUNICH, Germany and AMSTERDAM, Netherlands, Aug. ... B.V., the,pan-European specialty pharmaceutical company, today announced ... million revenue interest acquisition financing,agreement to fund ... other markets, from Procter & Gamble Pharmaceuticals. ...
Cached Biology Technology:China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 2China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 2Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 5Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 6Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 8Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 9Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 10Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 11Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 12Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 13Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 14Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 15Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 16Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 17Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 18Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 19Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 20Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 21TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 2TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 3TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 4TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 5
(Date:6/18/2013)... of Molecular Biology, has been honored as a ... Torrent is being recognized for his outstanding research, ... antimicrobial regions in proteins. Luis Rivas, Centro de ... algorithm to interrogate full genomes in order to ... results." , Torrent obtained his Ph.D. from ...
(Date:6/18/2013)... for Molecular Pathology is proud to announce it will ... (FASEB) on July 1, 2013. The FASEB Board approved ... , The 26 constituent societies of FASEB represent more ... the advancement of research and education in biological and ... important now than ever," said Jennifer L. Hunt, MD, ...
(Date:6/18/2013)... a chemical modification of DNA and this modification ... DNA sequence. Until now, scientists believed that this ... genes. Today, a team of researchers from the ... Dermitzakis, Louis-Jeantet Professor at the Faculty of Medicine, ... and that DNA methylation may play both a ...
Breaking Biology News(10 mins):The American Society for Microbiology honors Marc Torrent 2The secret of DNA methylation 2
... is a growing human health concern. Researchers around ... to be present in surface waters and sediments, ... In a recent article in the November-December issue ... State University (CSU) describe a study to find ...
... morality gives but a slight or no advantage to ... men of the same tribe...an advancement in the standard ... one tribe over another. With these ... and pro-social behaviors individuals behaving for the good of ...
... Britain over the past 17 years for extracting oil is ... heavy oilfield in Canada. Duvernay Petroleum is to ... the University of Bath at its site at Peace River ... is very viscous, like syrup, or even solid in its ...
Cached Biology News:Manure management reduces levels of antibiotics and antibiotic resistance genes 2Group selection, a theory whose time has come...again 2Massive Canadian oilfield could be exploited using new UK system 2Massive Canadian oilfield could be exploited using new UK system 3
Human Cystatin A MAb (Clone 224705)...
... Molecular Probes is pleased to ... for the ultrasensitive detection of primary ... at Indiana University, the ATTO-TAG reagents ... o-phthaldialdehyde (OPA), naphthalene-2,3-dicarboxaldehyde (NDA) and anthracene-2,3-dicarboxaldehyde, ...
...
Anti-SDF-1β/PBSF affinity isolated antibody lyophilized powder Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline recombinant human SDF-1β/PBSF expressed in E....
Biology Products: